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INTRODUCTION
Until recent approval of the first direct-acting 
antivirals against hepatitis C virus (HCV), the com-
bination of pegylated interferon and ribavirin was 
the standard therapy for chronic hepatitis C. Treat-
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ment achieves a sustained viral response (SVR) re-
lated to cure of disease in 41% to 56% of the pa-
tients infected with HCV genotype 1 (7). This gen-
otype prevails in Bulgaria (in ~85-87% of the popu-
lation). However, it is also known as a ‘difficult-to-
treat’ genotype. Among HCV genotype 1 patients’ 
population, SVR rate depends on diverse factors, as 
cirrhosis presence plays the most important predic-
tive role for treatment failure (5-7,9,11). Recent stud-
ies identify the genetic polymorphism in interleukin 
28b (IL28B) gene as a strong factor for spontaneous 
and interferon-induced viral clearance (14). Other 
considered predictors for suboptimal viral eradica-
tion are: high baseline viral load; previous therapeu-
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tic failure; patient’s age >40 years; male gender; body 
weight >75 kg or obesity; insulin resistance; concom-
itant steatosi;, elevated GGT level; high ferritin lev-
el; patient’s low motivation and non-adherence to 
therapy as well as cumulative exposure to interfer-
on and ribavirin and grade of hemoglobin reduction 
(4,6,10,12). Given the interferon-ribavirin treatment 
side-effects and healthcare costs, identifying the pa-
tients who are less probable ‘responders’ is highly de-
sirable. Some patients with unfavourable baseline 
characteristics could become appropriate candidates 
for new ‘triple’ treatment regimens, including direct 
acting antiviral drugs. 
The present study was designed to analyze 
baseline characteristics associated with SVR in 
most ‘difficult-to-treat’ genotype 1 patients with 
chronic hepatitis C at stage of advanced fibrosis 
and cirrhosis. 
MATERIAL AND METHODS
This observational trial included 163 patients 
diagnosed with chronic hepatitis C and treated in 
our referral center with peginterferon-alpha plus 
ribavirin under routine clinical practice conditions 
from 2004 to 2011. The target group consisted of 70 
patients with advanced hepatitis C: of them, 35 pre-
sented with advanced fibrosis (F3) and 35 with cir-
rhosis (F4). Data from treatment results were col-
lected from our medical records and were compared 
to therapy response of 93 consecutive patients with 
early stage of disease (F0-F2 fibrosis stages, accord-
ing to METAVIR). All the patients were registered 
as infected with HCV genotype 1 at baseline. Serum 
HCV RNA levels were evaluated at baseline, at week 
12 and at the end of follow-up. Measurements were 
done using quantitative real-time polymerase chain 
reaction Taqman assay (Amplisence, CRIE) with a 
lower limit of detection of 5 IU/mL. HCV RNA lev-
el higher than 600000 IU/mL was defined as high vi-
ral load. Stage of disease was assessed by liver biop-
sy according to Menghini technique. Fibrosis was ex-
amined by experienced pathologist using METAVIR 
scoring system (as score F0 to F4). Only five patients 
were invasively staged as cirrhotic based on firm liv-
er, ultrasound and endoscopic data for portal hyper-
tension. As the patients with advanced liver disease 
were eventually heterogeneous population, they were 
divided into three groups such as: bridging fibro-
sis (F3, n=35); fully compensated ‘histological’ cir-
rhosis (F4 with normal liver synthetic function, ab-
sence of esophageal varices and thrombocyte level 
>125х109/l, (n=23); cirrhosis and clinically significant 
portal hypertension - esophageal varices, splenomeg-
aly with hypersplenism and/or disturbed liver func-
tion assessed with Child-Pough score 6 or 7 (n=12). 
Therapy was administered per protocol of our cur-
rent National Consensus on treatment of chronic vi-
ral hepatitis in adult patients. Pegylated interferon al-
pha-2a (180 mcg s. c. per week) was given in addi-
tion with oral ribavirin (1000-1200 mg per day ac-
cording to body weight)) for 24 weeks in patients 
without early virologic response (EVR) and for 48 
weeks for patients who had achieved EVR. Then the 
patients were followed-up for at least 24 weeks after 
therapy completion and SVR was registered if HCV 
RNA remained negative at the end of following-up. 
The following variables were recorded at the start of 
treatment: patient’s age; gender; weight registered as 
three categories (normal, overweight and obesity); 
liver enzymes activity (ALT, AST, and GGT); vire-
mia level (HCV RNA) and histological activity (de-
fined as mild, moderate and severe). Bivariate anal-
ysis was carried out using Mann-Whitney’s t test for 
quantitative variables and the chi-square test as well 
as one-way ANOVA for the remaining qualitative 
variables. The statistical analysis was performed by 
means of a free version of GraphPad Prism 6.0 statis-
tical software.
RESULTS
Demographic data, clinical, laboratory 
and morphological findings in the target group 
of patients with advanced hepatitis C were 
summarized in Table 1. 
The mean age of the patients with bridging 
fibrosis was 47±13 years as compared to age of the 
patients with cirrhosis (56±9 years). There was no 
statistical difference in baseline viral load (Fig. 
1), transaminase levels and histological activity 
between the patients with advanced liver disease. 
A high baseline viral load was established in 38,6% 
of F3-F4 patients have.
There was a very high prevalence of diabetes 
mellitus in F3-F4 patients (in 45%), as most cases 
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were well-controlled on a diet. Prevalence of 
diabetes mellitus in F0-F2 patients of 2,5% reflected 
approximately the rates reported in the general 
population. Mean baseline platelet count was 
164x109/L (between 85 and 320x109/L). Besides, 
mean AST/ALT ratio was 0,86 emphasizing that the 
finding of AST/ALT >0,8 in screened patients might 
be a feature directed to the presence of advanced liver 
disease. 
Treatment was successful in 36 patients with 
advanced liver disease and established SVR rate of 
51,4% was significantly lower than excellent treatment 
response in 80,6% of the patients with F0-F2 fibrosis 
stage. Relapse and non-response rates in F3-F4 
patients were equal – 24,3%. Viral eradication 
rates were 60% in F3 patients, 55% in patients with 
‘histological’ cirrhosis and only 25% in 12 treated 
patients with portal hypertension and/or early liver 
synthetic dysfunction (Fig. 2). 
We did not establish any significant associa-
tion with SVR and the following baseline charac-
teristics: age, gender, weight, biochemical and histo-
logical activity between the treated patients with ad-
vanced liver disease. High viral load was not asso-
ciated with therapeutic failure within F0-F2-staged 
hepatitis C patients. In contrast, F3-F4 patients that 
had achieved SVR presented with a statistically sig-
nificantly lower baseline HCV RNA level (mean level 
Parameter n range / %
male/female ratio 33/37
mean age at diagnosis (years) 51,4 23-69
route of transmission
     - transfusion of blood / blood products 25 35,7
     - intravenous drug use 3 4,3
     - unknown 19 27,1
documentation for previous acute C (non-A, non-B) hepatitis 11 15,7
mean duration of infection (years) 24 10-42
daily alcohol consumption >50 mL 12 17,1
prevalence of overweight and obesity (BMI ≥25) 28 40
prevalence of diabetes mellitus 32 45,7
prevalence of symptoms of liver disease 48 68,6
Child-Pough score (in cirrhosis, n=35)
     - 5 27 77
     - 6 5 14
     - 7 3 9
platelets count (x 109/L) 164 85-320
mean ALT (U/L) 119 29-320
AST/ALT ratio 0,86
predominant GGT elevation 16 22,8
cholestasis (alkaline phosphatase) 4 5,7
high baseline viremia (>600000 IU/mL) 27 38,6
grade of histological activity (n=65)
     - mild 13 20
     - moderate 40 61,5
     - severe 12 18,5
grade of steatosis
     - absent 35 50
     - mild 24 34,2
     - moderate 7 10
     - severe 4 5,7
Table 1: Baseline characteristics of patients with advanced liver disease (n=70)
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of 440000 IU/mL) than ‘relapsers’ and non-respond-
ers to interferon-ribavirin therapy (mean level of 
997000 IU/mL) (Fig. 3).
In addition, SVR rate in the subgroup of 
patients with low viral load was 65% as compared 
to 30% among the patients with high initial level of 
HCV RNA (for this analysis set to above 600000 IU/
mL). The difference between these proportions was 
highly statistically significant.
DISCUSSION
The response to standard ‘bi-therapy’ with pe-
ginterferon and ribavirin is heterogeneous and is 
proved as suboptimal in hepatitis C patients infect-
ed with genotype 1 and those with advanced fibro-
sis (2,3,8). In order to investigate certain other im-
portant baseline factors associated with SVR we per-
formed this retrospective analysis focused on series 
of genotype 1 patients with advanced liver disease 
treated under routine clinical conditions. We found 
out that 51,4% of ‘naive’ patients with advanced fi-
brosis and cirrhosis achieved SVR. This response 
rate was comparable or even higher than that report-
ed in international trials with peginterferon-alpha 
plus ribavirin reaching results with a current ‘triple’ 
combination therapy for stage F3-F4 (1).
Baseline HCV viral load is an independent pre-
dictive factor of treatment response in pivotal studies 
(9,11,13,15). However, other analyses in clinical set-
tings do not confirm the assumption that viral load 
constitutes a predictive factor for treatment response 
(5). The successfully treated patients of ours are those 
who demonstrate a lower baseline viral load. Initial 
HCV RNA level is the only baseline factor associated 
with SVR in this patients’ population that challeng-
es for treatment. We have not performed any multi-
ple logistic regression analysis in the present small-
group study and this circumstance could be consid-
ered a methodological disadvantage. However, in our 
modest opinion, well-registered experience can be 
helpful in clinical decision making.
CONCLUSION
The most ‘difficult-to-treat’ patients with 
HCV genotype 1 and advanced liver disease may 
successfully receive a standard treatment with SVR 
rate of 51,4%, reaching the results of current ‘triple’ 
therapy for F3 and F4 stages. The viral eradication is 
associated with a low baseline viral load. According 
to our study, ‘naive’ HCV genotype 1 patients with 
baseline high viral load, portal hypertension and/or 
early liver synthetic dysfunction urgently necessitate 
triple combination therapy because of low chance of 
response to standard treatment.
REFERENCES 
1. Bourlière, M., A. Khaloun, C. Wartelle-Bladou, V. 
Oules, I. Portal, S. Benali, et al. Future treatment of 
Fig. 1. Baseline HCV RNA level in patients with advanced 
liver disease
Fig. 2. Therapeutic results in patients with advanced liver 
disease
Fig. 3. Baseline viral load in patients with advanced liver 
disease according to treatment response
Scripta Scientifica Medica, vol. 45, No 3, 2013, pp. 53-57
Copyright © Medical University of Varna   57
Irina Ivanova, Iskren Kotsev, Maria Atanassova et al.
patients with HCV cirrhosis.- Liver Int., 32, 2012, 
Suppl. 1, 113-119.
2. Cheng, W. S., S. K. Roberts, G. McCaughan, 
W. Sievert, M. Weltman, D. Crawford,  et al.; 
CHARIOT Study Group. Low virological response 
and high relapse rates in hepatitis C genotype 1 
patients with advanced fibrosis despite adequate 
therapeutic dosing.- J. Hepatol., 53, 2010, No 4, 
616-623.
3. Di Marco, V., P. L. Almasio, D. Ferraro, V. 
Calvaruso, G. Alaimo, S. Peralta, et al. Peg-
interferon alone or combined with ribavirin 
in HCV cirrhosis with portal hypertension: a 
randomized controlled trial.- J. Hepatol., 47, 2007, 
No 4, 484-491.
4. Ferenci, P. Predicting the therapeutic response in 
patients with chronic hepatitis C: the role of viral 
kinetic studies.- J. Antimicrob. Chemother., 53, 
2004, No 1, 15-18.
5. García-Samaniego, J., M. Romero, R. Granados, 
R. Alemán, M. Jorge Juan, D. Suárez, et al. Factors 
associated with early virological response to 
peginterferon-α-2a/ribavirin in chronic hepatitis 
C.- World J. Gastroenterol., 19, 2013, No 12, 
1943-1952.
6. Gheorghe, L., S. Iacob, I. Sporea, M. Grigorescu, 
R. Sirli, D. Damian,  et al. Efficacy, tolerability and 
predictive factors for early and sustained virologic 
response in patients treated with weight-based 
dosing regimen of PegIFN alpha-2b ribavirin in 
real-life healthcare setting.- J. Gastrointestin. Liver 
Dis., 16, 2007, No 1, 23-29.
7. Hadziyannis, S. J., J. H. Sette, T. R. Morgan, V. 
Balan, M. Diago, P. Marcellin, et al.; PEGASYS 
International Study Group. Peginterferon-alpha2a 
and ribavirin combination therapy in chronic 
hepatitis C: a randomized study of treatment 
duration and ribavirin dose.- Ann. Intern. Med., 
140, 2004, No 5, 346-355.
8. Helbling, B., W. Jochum, I. Stamenic, M. Knöpfli, 
A. Cerny, J. Borovicka, et al.; Swiss Association 
for the Study of the Liver (SASL). HCV-related 
advanced fibrosis/cirrhosis: randomized controlled 
trial of pegylated interferon alpha-2a and 
ribavirin.- J. Viral Hepat., 13, 2006, No 11, 762-769.
9. Jensen, D. M., T. R. Morgan, P. Marcellin, P. J. 
Pockros, K. R. Reddy, S. J. Hadziyannis, et al. 
Early identification of HCV genotype 1 patients 
responding to 24 weeks peginterferon alpha-2a (40 
kd)/ribavirin therapy.- Hepatology, 43, 2006, No 5, 
954-960.
10. Lindsay, K. L., C. Morishima, E. C. Wright, J. L. 
Dienstag, M. L. Shiffman, G. T. Everson, et al.; 
HALT-C Trial. Blunted cytopenias and weight 
loss: new correlates of virologic null response 
to re-treatment of chronic hepatitis C.- Clin. 
Gastroenterol. Hepatol., 6, 2008, No 2, 234-241. 
11. Mangia, A., N. Minerva, D. Bacca, R. Cozzolongo, 
G. L. Ricci, V. Carretta, et al. Individualized 
treatment duration for hepatitis C genotype 
1 patients: a randomized controlled trial.- 
Hepatology, 47, 2008, No 1, 43-50.
12. Reddy, K. R., D. Messinger, M. Popescu, S. J. 
Hadziyannis. Peginterferon alpha-2a (40 kDa) 
and ribavirin: comparable rates of sustained 
virologicaln response in sub-sets of older and 
younger HCV genotype 1 patients.- J. Viral Hepat., 
16, 2009, No 10, 724-731.
13. Rodriguez-Torres, M., M. S. Sulkowski, R. Chung, 
F. M. Hamzeh, D. M. Jensen. Factors associated 
with rapid and early virologic response to 
peginterferon alfa-2a/ribavirin treatment in HCV 
genotype 1 patients representative of the general 
chronic hepatitis C population.- J. Viral Hepat., 17, 
2010, No 2, 139-147.
14. Thompson, A. J., A. J. Muir, M. S. Sulkowski, D. 
Ge, J. Fellay, K. V. Shianna, et al. Interleukin-
28B polymorphism improves viral kinetics and is 
the strongest pretreatment predictor of sustained 
virologic response in genotype 1 hepatitis C virus.- 
Gastroenterology, 139, 2010, No 1, 120-129.
15. Yu, M. L., C. Y. Dai, J. F. Huang, C. F. Chiu, Y. H. 
Yang, N. J. Hou, et al. Rapid virological response 
and treatment duration for chronic hepatitis 
C genotype 1 patients: a randomized trial.- 
Hepatology, 47, 2008, No 6, 1884-1893. 
